OPRX
OptimizeRx CorpPrice
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
- R Mar 5 OptimizeRx reported strong 2025 financial results with record revenu…
- R Mar 5 OptimizeRx (OPRX) reported solid Q4 and full-year 2025 results with…
- R Mar 5 OptimizeRx reported strong Q4 and full-year 2025 results with record…
- R May 12 OptimizeRx reported Q1 2026 revenue of $19.8M (down 10% YoY) and a G…
- R Aug 12 OptimizeRx reported Q2 2026 revenue of $20.5M and EPS of $0.14, beat…
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.
- InstitutionsBEARISH
Q2 2026: 13 added (0 new), 24 trimmed or exited.
- AnalystsBULLISH
11 of 12 rate it Buy or better. Every target is above the price.
- EstimatesFALLING
Current-quarter EPS estimate $0.246 → $0.162 over 90 days. 0 up, 1 down in 30 days.
- TrendUPTREND
14% above its 50-day average.
- SocialQUIET
No Reddit mentions this week. Last mention Oct 19.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| BlackRock, Inc. | TRIM | $2.5M |
| GEODE CAPITAL MANAGEMENT, LLC | TRIM | $1.2M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | TRIM | $969.8K |
| MARSHALL WACE, LLP | DOUBLED | $927.7K |
| MORGAN STANLEY | DOUBLED | $894.1K |
| GOLDMAN SACHS GROUP INC | TRIM | $600.8K |
| Quantinno Capital Management LP | DOUBLED | $567.0K |
| Trexquant Investment LP | TRIM | $512.9K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
12 analystsPrice is below the lowest target. Median implies +19%.Targets as of Oct 27, 2026.
| Date | Firm | Rating |
|---|---|---|
| Sep 29, 2026 | B. Riley Securities MAINTAIN | Buy |
| Aug 14, 2026 | Citizens MAINTAIN | Market Outperform |
| May 13, 2026 | Lake Street MAINTAIN | Buy |
| May 13, 2026 | B. Riley Securities MAINTAIN | Buy |
| May 13, 2026 | Stephens & Co. MAINTAIN | Equal-Weight |
| May 13, 2026 | Stifel MAINTAIN | Buy |
Insider ledger
Form 4| Date | Insider | Type | Value |
|---|---|---|---|
| Oct 1, 2026 | D'Silva Andrew J. Chief Business Officer | TAX W/H | $3.5K |
| Sep 1, 2026 | D'Silva Andrew J. Chief Business Officer | TAX W/H | $11.3K |
| Aug 21, 2026 | Silvestro Stephen L Chief Executive Officer | TAX W/H | $13.4K |
| Aug 21, 2026 | Merrell Brendan W. CHIEF OPERATING OFFICER | TAX W/H | $7.9K |
| Aug 21, 2026 | Stelmakh Edward Chief Finance & Strat Officer | TAX W/H | $10.6K |
| Aug 21, 2026 | D'Silva Andrew J. Chief Business Officer | TAX W/H | $9.6K |
| Aug 21, 2026 | Odence-Ford Marion Chief Legal & Admin Officer | TAX W/H | $11.8K |
| Aug 20, 2026 | Silvestro Stephen L Chief Executive Officer | AWARD | 79,200 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | $0.16 | $0.10–$0.22 | -4.7% | $21.2M |
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | $0.88 | $0.72–$0.99 | -1.6% | $96.2M |
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 15, 2026SecBot reports
9 filings · 4 press releases · 2 bullish · 0 bearish · 3 mixed · 4 neutral- NEUTRAL PRESS RELEASEOct 27, 2026
OptimizeRx announced a partnership with PulsePoint to make its authenticated EHR and e-prescribing inventory available to PulsePoint clients via programmatic buying, expanding PulsePoint's programmatic EHR reach to over 1 million NPIs. The integration is expected to launch in November 2026.
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL SC 13G/AOct 21, 2026
Royce & Associates LP filed an amended Schedule 13G for OptimizeRx Corp, disclosing beneficial…
Monitor for any future conversion to Schedule 13D (activist intent) or significant changes in Royce's position. The 6.98% stake is just below the 10% threshold that would trigger additional…
- MIXED INST-CLUSTERSep 22, 2026
In Q2 2026, OptimizeRx saw a mixed institutional cluster: 13 buyers (led by Marshall Wace, Morgan…
The divergence between active quant buying and mega-passive selling suggests a potential catalyst-driven thesis among informed managers, but the net outflow and lack of insider corroboration warrant…
- BULLISH PRESS-RELEASEAug 12, 2026
OptimizeRx reported Q2 2026 revenue of $20.5M and EPS of $0.14, beating consensus estimates of…
The EPS beat and debt refinancing are positive, but the reaffirmation of existing guidance without an upgrade limits the upside catalyst.
All OPRX filing & press-release reports (13)
- PRESS-RELEASE reportOct 27, 2026
- SC 13G/A reportOct 21, 2026
- INST-CLUSTER reportSep 22, 2026
- PRESS-RELEASE reportAug 12, 2026
- 8-K reportJun 12, 2026
- INST-CLUSTER reportJun 11, 2026
- 8-K reportJun 5, 2026
- DEFA14A reportJun 1, 2026
- PRESS-RELEASE reportMay 21, 2026
- PRESS-RELEASE reportMay 12, 2026
- PRESS-RELEASE reportMar 5, 2026
- 8-K reportMar 5, 2026
- PRESS-RELEASE reportMar 5, 2026